Albireo to Present at the Jefferies 2019 London Healthcare Conference
15 November 2019 - 12:30AM
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan
pediatric liver disease company developing novel bile acid
modulators, today announced that Ron Cooper, President and Chief
Executive Officer, will present at the Jefferies 2019 London
Healthcare Conference on Thursday, November 21, 2019, at 5:20 p.m.
GMT (12:20 p.m. EST).
A live audio webcast of the presentation will be accessible from
the Media & Investors page of Albireo’s
website, ir.albireopharma.com. To ensure a timely connection
to the webcast, it is recommended that users register at least 15
minutes prior to the scheduled start time. An archived version of
the webcast will be available for replay in the Events &
Presentations section of the Media & Investors page of
Albireo’s website for at least two weeks following the event.
About AlbireoAlbireo Pharma is a
clinical-stage biopharmaceutical company focused on the development
of novel bile acid modulators to treat orphan pediatric liver
diseases, and other liver and gastrointestinal diseases and
disorders. Albireo’s lead product candidate, odevixibat, is being
developed to treat rare pediatric cholestatic liver diseases and is
in Phase 3 development in its initial target indication,
progressive familial intrahepatic cholestasis (PFIC). Albireo’s
clinical pipeline also includes two Phase 2 product candidates.
Elobixibat is in Phase 2 development in NAFLD and NASH. Approved
in Japan for the treatment of chronic constipation,
elobixibat is the first ileal bile acid transporter (IBAT)
inhibitor approved anywhere in the world.
Albireo was spun out from AstraZeneca in
2008. Albireo Pharma is located in Boston, Mass.,
and its key operating subsidiary is located in Gothenburg,
Sweden. The Boston Business Journal named Albireo one of
the 2019 Best Places to Work in Massachusetts. For more
information on Albireo, please
visit www.albireopharma.com.
Investor Contact: Hans Vitzthum, LifeSci
Advisors, LLC, 617-430-7578Media Contact: Heather
Anderson, 6 Degrees, 980-938-0260,
handerson@6degreespr.com
Source: Albireo Pharma, Inc.
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Apr 2024 to May 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From May 2023 to May 2024